register

ESG

Hepatitis Australia announces new CEO

Health Industry Hub | March 6, 2020 |

Hepatitis Australia has appointed Carrie Fowlie as its incoming Chief Executive Officer.

Following the retirement of Helen Tyrrell at the beginning of February, Hepatitis Australia undertook a rigorous recruitment process to identify the person to take over the operational leadership of the organisation and work closely with the Board.

Hepatitis Australia President, A/Prof. Grant Phelps said, “the Board is delighted that Carrie has accepted the position of CEO.  Carrie brings deep experience and knowledge of the sector and is well known to and highly regarded by many who have worked with Hepatitis Australia.”

“Carrie is very well positioned to assist the Board and staff of Hepatitis Australia to continue to drive towards improving the lives of people with hepatitis B and hepatitis C and our vison of an end to viral hepatitis in Australia”

Carrie heads to Hepatitis Australia with almost two decades of peak body experience.

Carrie has extensive representational experience at the national and international level. Her work with elected officials and their offices, in parliaments, at the United Nations and with government officials has resulted in policies that are consistent with the evidence and the priorities of the constituencies she has represented.

Carrie Fowlie said, “the leadership of Hepatitis Australia with its members, affected communities, the sector and allies over the past decade has been transformative.”

“What an extraordinary opportunity, working together to achieve a shared goal of eliminating viral hepatitis by 2030.”

“I look forward to contributing to the health and wellbeing and strengthening the voices of around 400,000 Australians living with hepatitis B or hepatitis C and those who represent them.”

Acting CEO, Kevin Marriott says, “the staff team at Hepatitis Australia is excited to welcome Carrie and we look forward to her leadership and guidance into the future.

Carrie Fowlie will formally commence with Hepatitis Australia in mid-April, 2020.

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.